Status:
RECRUITING
Monitoring of Donor-specific Antibodies After Treatment with Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation
Lead Sponsor:
Hannover Medical School
Conditions:
Lung Transplantation
Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies
Eligibility:
All Genders
Brief Summary
Single-arm, prospective observational study
Detailed Description
This is an observational study to monitor the treatment of donor-specific antibodies in lung transplant recipients with detection of donor-specific antibodies. All consented subjects will be approache...
Eligibility Criteria
Inclusion
- all patients after lung transplantation with detection of donor-specific antibodies
Exclusion
- none
Key Trial Info
Start Date :
October 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT03798860
Start Date
October 1 2018
End Date
December 1 2026
Last Update
October 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery
Hanover, Germany